Johnson & Johnson Says DePuy Synthes Receives FDA Clearance For TriLeap Lower Extremity Anatomic Plating System; DePuy Synthes Expects The TriLeap Lower Extremity Anatomic Plating System To Be Available In U.S. In 2024
Portfolio Pulse from Benzinga Newsdesk
Johnson & Johnson's DePuy Synthes has received FDA clearance for its TriLeap Lower Extremity Anatomic Plating System. The system is expected to be available in the U.S. in 2024.
October 11, 2023 | 6:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Johnson & Johnson's DePuy Synthes division has received FDA clearance for its TriLeap Lower Extremity Anatomic Plating System, which is expected to be available in the U.S. in 2024.
The FDA clearance for the TriLeap Lower Extremity Anatomic Plating System is a positive development for Johnson & Johnson. This could potentially lead to increased revenues in the future once the product is available in the U.S. market. However, as the product is expected to be available in 2024, the immediate impact on the stock price may be limited.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100